Close Menu

    Diabetes & Glycaemic Control

    Diabetes and glycaemic-control evidence summaries covering HbA1c, glucose monitoring, medication comparisons, hypoglycaemia, patient-reported outcomes, and clinical interpretation.

    Landmark Cardiovascular Outcomes

    CARDS: Atorvastatin Reduces Cardiovascular Events by 37% and Stroke by 48% in Type 2 Diabetes Regardless of LDL Level

    CARDS demonstrated that atorvastatin 10 mg reduces major cardiovascular events by 37% and stroke by 48% in patients with type 2 diabetes and normal to mildly elevated LDL-cholesterol without prior CVD, confirming that cardiovascular risk rather than LDL level should determine statin initiation and establishing universal statin use in primary cardiovascular prevention for type 2 diabetes.

    Landmark Cardiovascular Outcomes

    Heart Protection Study: Simvastatin Reduces Vascular Events by 24% in All High-Risk Patients Regardless of Baseline LDL

    HPS demonstrated that simvastatin reduces major vascular events by 24% across all high-risk patients regardless of baseline LDL-cholesterol level, including those with diabetes without established coronary disease, eliminating the treatment threshold concept and establishing absolute cardiovascular risk as the primary criterion for statin therapy — one of the most influential results in preventive cardiology.

    Landmark Cardiovascular Outcomes

    VADT: Intensive Glucose Control Provides No Cardiovascular Benefit in Long-Standing High-Risk Type 2 Diabetes

    VADT demonstrated that intensive glucose control achieving a median HbA1c of 6.9% did not significantly reduce cardiovascular events or mortality in veterans with long-standing type 2 diabetes and high cardiovascular disease prevalence, completing the ACCORD/ADVANCE/VADT triptych that defined the limits of aggressive glycaemic management in advanced disease.

    Landmark Diabetes & Glycaemic Control

    ADVANCE: Intensive Glucose Control Reduces Nephropathy by 21% in High-Risk Type 2 Diabetes Without Mortality Harm

    ADVANCE demonstrated that intensive glucose control targeting HbA1c below 6.5% using a gliclazide-based strategy reduces nephropathy by 21% and the microvascular composite by 14% in high-risk type 2 diabetes, without the mortality hazard observed in ACCORD, providing important context for how glycaemic targets and treatment strategies interact with safety outcomes.

    Landmark Cardiovascular Outcomes

    ACCORD: Targeting HbA1c Below 6.0% Increases Mortality by 22% in High-Risk Type 2 Diabetes

    ACCORD demonstrated that targeting an HbA1c below 6.0% in high-risk type 2 diabetes patients with established cardiovascular disease increased all-cause mortality by 22% without significantly reducing cardiovascular events, establishing that very intensive glycaemic targets are harmful in this population and reshaping international guidelines to mandate individualised HbA1c targeting.

    Landmark Cardiovascular Outcomes

    Steno-2: Multifactorial Intervention Reduces All-Cause Mortality by 46% and Cardiovascular Events by 59% in High-Risk Type 2 Diabetes

    Steno-2 demonstrated that intensive multifactorial risk factor intervention targeting glycaemia, blood pressure, lipids, and lifestyle simultaneously reduces all-cause mortality by 46% and cardiovascular events by 59% over 13.3 years in type 2 diabetes with microalbuminuria, providing the defining evidence for comprehensive cardiovascular risk management in high-risk type 2 diabetes.

    Landmark Cardiovascular Outcomes

    UKPDS 38: Tight Blood Pressure Control Reduces Stroke by 44% and Diabetes Complications by 24–37% in Type 2 Diabetes

    UKPDS 38 demonstrated that tight blood pressure control targeting below 150/85 mmHg reduces stroke by 44%, diabetes-related endpoints by 24%, and microvascular complications by 37% in hypertensive type 2 diabetes over 8.4 years, establishing blood pressure control as a therapeutic target of at least equal macrovascular importance to glycaemic management.

    Landmark Cardiovascular Outcomes

    UKPDS 34: Metformin Reduces Mortality by 36% in Overweight Type 2 Diabetes — Establishing First-Line Standard of Care

    UKPDS 34 demonstrated that metformin reduces diabetes-related endpoints, death, and all-cause mortality by 32–42% in overweight patients with newly diagnosed type 2 diabetes, with superior cardiovascular outcomes compared with sulphonylurea or insulin, establishing metformin as the preferred first-line pharmacological therapy for type 2 diabetes for the subsequent three decades.

    Landmark Diabetes & Glycaemic Control

    UKPDS 33: Intensive Glucose Control Reduces Microvascular Complications by 25% in Newly Diagnosed Type 2 Diabetes

    UKPDS 33 established that intensive blood-glucose control with sulphonylurea or insulin reduces microvascular complications by 25% in newly diagnosed type 2 diabetes over 10 years with a 0.9% HbA1c differential, confirming the glucose hypothesis for type 2 diabetes microvascular disease and forming the foundational evidence for tight glycaemic management from diagnosis.

    Landmark Cardiovascular Outcomes

    EDIC: Metabolic Memory — Early Intensive Therapy Reduces Cardiovascular Events by 42–57% Over 17 Years in Type 1 Diabetes

    The EDIC study demonstrated that 6.5 years of intensive glycaemic therapy during the DCCT reduced cardiovascular events by 42–57% over 17 years of follow-up despite subsequent HbA1c convergence between groups, establishing the concept of metabolic memory and providing foundational evidence that early intensive glycaemic control produces durable cardiovascular protection extending decades beyond the intervention period.

    Subscribe now

    Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

    CATEGORIES

    CONTACT INFO

    Contact Us

    © 2024-2026 Hormone Insight. All rights reserved.